<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990743</url>
  </required_header>
  <id_info>
    <org_study_id>2008-008204-41</org_study_id>
    <secondary_id>CUNFI-0511-0814</secondary_id>
    <nct_id>NCT00990743</nct_id>
  </id_info>
  <brief_title>Tolerance and Effect on Intraocular Pressure After Administration of SYL040012</brief_title>
  <official_title>Phase I Study With SYL040012. Tolerance and Effect on Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether SYL040012 is safe for the treatment of
      ocular hypertension and glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Local tolerance after administration of one dose of SYL040012.</measure>
    <time_frame>Part I: 3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Local tolerance after 7 days administration of SYL040012 with one dose per day.</measure>
    <time_frame>Part II: 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Period I: Local Tolerance Assessment, Effect Assessment &amp; Pharmacokinetic description after administration of one dose of SYL040012.Side effects. Analytics.</measure>
    <time_frame>Part I: 1 hour, 1, 2, 3, days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period II:Tolerance assessment, Pharmacokinetic description, Effect assessment on the IOP after 7 days administration. Side effects. Analytics</measure>
    <time_frame>Part II: After each administration, at time 1 and 96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>SYL040012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYL040012</intervention_name>
    <description>Administration of single and multiple doses of SYL040012 in ophthalmic drops solution</description>
    <arm_group_label>SYL040012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, any gender

          -  18 to 45 years of age,

          -  Subjects must provide signed informed consent prior to participation in any
             study-related procedures

          -  Body Mass Index between 19,5 and 29 kg/m2

          -  IOP &lt;/= 21 mmHg in both eyes

          -  Have a BCVA (Best corrected visual acuity) of &gt;/= 0.8 (20/25) (Snellen scale), or &lt;/=
             0.1 (LogMar units)in both eyes

          -  Normal Fluorescein Clearance Test in both eyes

          -  Normal funduscopy in both eyes

        Exclusion Criteria:

          -  Pregnant or breastfeeding females or those with a positive pregnancy test. Females of
             childbearing potential who will not use a medically acceptable contraceptive method
             from selection and during the hole study.

          -  Current relevant disease, including respiratory disease, cardiovascular, endocrine,
             neurological, haematological, renal, neoplastic, hepatopathy, gastrointestinal
             distress, hypertension, or infectious acute processes

          -  Previous chronic processes or with rebound characteristics that could interfere with
             study according to the investigator's judgment.

          -  Volunteers who have received pharmacological treatment, including medicinal plants,
             during the four weeks previous to beginning the study.

          -  Having used anti-cholinergics, betablockers and corticoids sporadically in the last 30
             days whichever the route of administration, or any med by ocular or nasal
             administration route.

          -  Case history of hypersensitivity to meds or any other allergic process

          -  Visual alterations: Previous eye surgery, glaucoma, uveitis or ocular surface
             pathology (dry eye, blepharitis).

          -  Volunteers with visual alteration with more than 3 dioptres in either eye

          -  Use of contact lenses

          -  Volunteer who has participated in a clinical trial during the past four months before
             study entry.

          -  Blood or derivate transfusion during the six previous months to study entry

          -  Case history of drug or alcohol abuse or dependence.

          -  Positive result in test drug abuse during selection period

          -  Positive serology results to hepatitis B virus (HbsAg), virus C or HIV

          -  Analytic alterations medically relevant, at investigator's judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belen Sadaba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Universitaria de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>October 21, 2010</last_update_submitted>
  <last_update_submitted_qc>October 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ana Isabel Jiménez</name_title>
    <organization>Sylentis</organization>
  </responsible_party>
  <keyword>Ocular hypertension</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Beta-blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

